by Michael Shanler | August 5, 2014 | Comments Off on 2014 Life Science Hype Cycle has published
Fifty technologies are profiled by Gartner analysts in this year’s Hype Cycle for Life Sciences, 2014. This is the most densely packed hype cycle since the LS HC introduction in 2003. This year, we added 8 new profiles and renamed a few others (with justification) to reflect the latest technology evolution. The sheer volume of profiles reiterate that IT and technology are becoming more pervasive and are redefining the boundaries of this industry. Some of these new technologies are in the tech “trigger” phase. A handful of others were added, reflecting our expanded area of coverage (and some tenacious prodding by clients.)
My last blog post was centered on the “digital transformation” required by the industry as a whole. While the message for the next few years is surely “digital”, there are a lot of questions about how and when to make investments in technology. The move to digital will require both cutting edge and mature technologies. As a reminder, just because a technology might be on the upswing “trigger” on our curve, it does not automatically mean that you must make the investment. Likewise, technologies in the “trough” don’t automatically mean that it is not the right answer for your organization’s challenge. You can find a refresher on how to interpret a hype cycle in these documents using these links:
- Understanding Gartner’s Hype Cycles
- Tech Go-to-Market: Using Gartner Hype Cycles to Refine Technology Marketing Strategies and Tactics
The information in this life science hype cycle is useful for business and IT leaders that are leading the digital transformation at pharma, biotech, CRO, CMOs and medical device companies. This includes early stage research, clinical development, quality, legal, manufacturing, supply chain, ops, med affairs, regulatory, sales, and marketing organizations.
Predicts 2019: Data and Analytics Strategy
Data and analytics are the key accelerants of digitalization, transformation and “ContinuousNext” efforts. As a result, data and analytics leaders will be counted upon to affect corporate strategy and value, change management, business ethics, and execution performance.Read Free Gartner Research
Category: 3d-printing additive-manufacturing analytics clinical-development ctms data-and-analytics-strategies eclinical edc engineering epro gartner innovation internet-of-everything internet-of-things iot it manufacturing nexus-of-forces nof pharmaceutical product-development rd science wearables
Tags: 3d-printing 3dp 3dprinting additive-manufacturing big-data bigdata collaboration digital eln engineering-2 informatics innovation iot it life-science lims nexus pharma plm product-development-2 prototyping rd science-2
Comments or opinions expressed on this blog are those of the individual contributors only, and do not necessarily represent the views of Gartner, Inc. or its management. Readers may copy and redistribute blog postings on other blogs, or otherwise for private, non-commercial or journalistic purposes, with attribution to Gartner. This content may not be used for any other purposes in any other formats or media. The content on this blog is provided on an "as-is" basis. Gartner shall not be liable for any damages whatsoever arising out of the content or use of this blog.